IGF-binding protein-derived peptide

Details IGF-binding protein-derived peptide IGF-binding protein-derived peptide

2005-03-01

2005-03-01

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

06861406

ABSTRACT:
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.

REFERENCES:
patent: 5187151 (1993-02-01), Clark et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5643867 (1997-07-01), Maack et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5723441 (1998-03-01), Higley et al.
patent: 5840673 (1998-11-01), Buckbinder et al.
patent: 5861273 (1999-01-01), Olson et al.
patent: 5914254 (1999-06-01), Mascarenhas et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 6015786 (2000-01-01), Mascarenhas et al.
patent: 6417330 (2002-07-01), Mascarenhas et al.
patent: 20020165155 (2002-11-01), Schaffer et al.
patent: 20030035788 (2003-02-01), Mascarenhas
patent: 20030092631 (2003-05-01), Deshayes et al.
patent: 0 128 733 (1984-12-01), None
patent: 0 597 033 (1993-02-01), None
patent: WO 9503817 (1995-02-01), None
patent: WO 9513823 (1995-05-01), None
patent: WO 9602565 (1996-02-01), None
patent: 23469 (2000-04-01), None
patent: WO 0187238 (2001-11-01), None
patent: WO 0224216 (2002-03-01), None
patent: WO 0234916 (2002-05-01), None
Asin, J. et al. (2000), “Iron (II) Induces Changes in the Conformation of Mammalian Mitochondrial DNA Resulting in a Reduction of its Transcriptional Rate,”FEBS Letters480:161-164.
Bartfay, W. J. et al. (1999). “A Biochemical, Histochemical, and Electron Microscopic Study on the Effects of Iron-Loading on the Hearts of Mice,”Cardiovascular Pathology8(6):305-314.
Ferrucci, J.T. (1991). “Iron Oxide Enhanced MR Imaging of the Liver and Spleen: Review of the First Five Years,”Keio J. Med. 40(4):206-214.
Green, D.A. et al. (2001). “Inhibiton of Malignant Cell Growth by 311, a Novel Iron Chelator of the Pyridoxal Isonicotinoyl Hydrazone Class: Effect on the R2 Subunit of Ribonucleotide Reductase,”Clinical Cancer Research7:3574-3579.
Hilger, I. et al. (2002). “Thermal Ablation of Tumors Using Magnetic Nanoparticles: An In Vivo Feasibility Study,”Investigative Radiology37(10):580-586.
Horwitz, L.D. et al. (1998). “Lipophilic Siderophores ofMycobacterium tuberculosisPrevent Cardiac Reperfusion Injury,”Proc. Natl. Acad. Sci. USA95:5263-5268.
Kato, I. et al. (1999). “Iron Intake, Body Iron Stores and Colorectal Cancer Risk in Women: A Nested Case-Control Study,”Int. J. Cancer80:693-698.
Logroscino, G. et al. (1997). “Altered Systemic Iron Metabolism in Parkinson's Disease,”Neurology49:714-717.
Mack, M.G. et al. (2002). “Superparamagnetic Iron Oxide-Enhanced MR Imaging of Head and Neck Lymph Nodes,”Radiology222(1):239-244.
Morris, C.J. et al. (1995). “Reactive Oxygen Species and Iron—A Dangerous Partnership in Inflammation,”Int. J. Biochem Cell. Biol. 27(2):109-122.
Parkes, J.G. et al. (1997). “Characterization of Fe2+and Fe3+Transport by Iron-Loaded Cardiac Myocytes,”Toxicology117:141-151.
Rosenthal, E.A. et al. (2001). “An Iron-Binding Exochelin Prevents Restenosis Due to Coronary Artery Balloon Injury in a Porcine Model,”Circulation104:2222-2227.
Schmitz, S.A. et al. (2001). “Magnetic Resonance Imaging of Atherosclerotic Plaques Using Superparamagnetic Iron Oxide Particles,”Journal of Magnetic Resonance Imaging14:355-361.
Shinkai, M. et al. (2001). “Targeting Hyperthermia for Renal Cell Carcinoma Using Human MN Antigen-Specific Magnetoliposomes,”Jpn. J. Cancer Res. 92:1138-1145.
Simonart, T. et al. (2002). “Antiproliferative and Apoptotic Effects of Iron Chelators on Human Cervical Carcioma Cells,”Gynecologic Oncology85:95-102.
Singh, N.P. and Lai, H. (2001). “Selective Toxicity of Dihydroartemisinin and Holotransferrin Toward Human Breast Cancer Cells,”Life Sciences70:49-56.
Taupitz, M. et al. (1993). “MR Lymphography Using Iron Oxide Particles,”Acta Radiologica34(1):10-15.
Weber, J. et al. (1988). “Decreased Iron Absorption in Patients with Active Rheumatoid Arthritis, With and Without Iron Deficiency,”Annals of the Rheumatic Diseases47:404-409.
Yang, D.C. et al. (2002). “Antisense Ferritin Oligonucleotides Inhibit Growth and Induce Apoptosis in Human Breast Carcinoma Cells,”Anticancer Research22:1513-1524.
Genbank accession No. BC031217, Jun. 13, 2002, located at <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21411477 &dopt=GenBank> visited on Feb. 14, 2003. (Two pages.).
Adams, S. et al. (1995). “Pharmacokinetics and Bioavailability of rhIGF-I/IGFBP-3 in the Rat and Monkey,”Prog. Growth Factor Res. 6(2-4):347-356.
Altschul, S.F. et al. (1990). “Basic Local Alignment Search Tool,”J. Mol. Biol. 215:403-410.
Ausubel, F. et al. eds. (1987).Current Protocols in Molecular BiologyGreene Publishing Associates and Wiley-Interscience: New York. (Table of Contents Only.).
Baxter, R.C. (1988). “Characterization of the Acid-Labile Subunit of the Growth Hormone-Dependent Insulin-Like Growth Factor Binding Protein Complex,”J. Clin. Endocrinol. Metab. 67(2):265-272.
Baxter, R.C. et al. (1986). “Growth Hormone-Dependent Insulin-Like Growth Factor (IGF) Binding Protein from Human Plasma Differs from Other Human IGF Binding Proteins,”Biochem. Biophys. Res. Comm. 139(3):1256-1261.
Baxter, R.C. et al. (1989). “High Molecular Weight Insulin-Like Growth Factor Binding Protein Complex,”J. Biol. Chem264(20):11843-11848.
Bayes-Genis, A. et al. (2001). “Insulin-Like Growth Factor Binding Protein-4 Protease Produced by Smooth Muscle Cells Increases in the Coronary Artery After Angioplasty,”Arterioscler. Thromb. Vasc. Biol. 21:335-341.
Blum, W.F. and Ranke, M.B. (1991). “Plasma IGFBP-3 Levels as Clinical Indicators”In Modern Concepts of Insulin-Like Growth FactorsSpencer, E.M. ed., Elsevier: New York. pp. 381-393.
Boles, B.K. et al. (2000). “Phorbol Ester-Induced U-937 Differentiation: Effects on Integrin α5Gene Transcription,”Am. J. Physiol. Lung Cell Mol. Physiol. 278:L703-L712.
Butler, A.A. et al. (1998). “Stimulation of Tumor Growth by Recombinant Human Insulin-Like Growth Factor-I (IGF-I) Is Dependent on the Dose and the Level of IGF-I Receptor Expression,”Cancer Res. 58:3021-3027.
Byun, D. et al. (2001). “Pregnancy-Associated Plasma Protein-A Accounts for the Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Proteolytic Activity in Human Pregnancy Serum and Enhances the Mitogenic Activity of IGF by Degrading IGFBP-4 in Vitro,”J. Clin. Endocrinol. Metab. 86(2):847-854.
Campbell, P.G. et al. (1998). “Plasminogen Binds the Heparin-Binding Domain of Insulin-Like Growth Factor-Binding Protein-3,”Am. J. Physiol. 275(2pt. 1):E321-E331.
Campbell, P.G. et al. (1999). “Insulin-Like Growth Factor-Binding Protein-3 Binds Fibrinogen and Fibrin,”J. Biol. Chem. 274(42):30215-30221.
Collett-Solberg, P.F. et al. (1998). “Identification of Novel High Molecular Weight Insulin-Like Growth Factor-Binding Protein-3 Association Proteins in Human Serum,”J. Clin. Endocrinol. Metab. 83(8):2843-2848.
Conover, C.A. et al. (2001). “Pregnancy-Associated Plasma Protein-A is the Insulin-Like Growth Factor Binding Protein-4 Protease Secreted by Human Ovarian Granulosa Cells and Is a Marker of Dominant Follicle Selection and the Corpus Luteum,”Endocrinology142(5):2155-2158.
Coppack, S.W. (2001). “Pro-Inflammatory Cytokines and Adipose Tissue,”Proc. Nutr. Soc. 60:349-356.
Crofford, L.J. (May, 2002). “Specific Cyclooxygenase-2 Inhibitors: What Have We Learned Since They Came Into Widespread Clinical Use?”Curr. Opin. Rheumatol. 13:225-230.
Du

Affiliated with

Also associated with

Rating

IGF-binding protein-derived peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IGF-binding protein-derived peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF-binding protein-derived peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3388765